Connect with us

Business

Owners of OxyContin Maker Paid $19M to Institution That Advises Opioid Policy

Published

on

The Sackler Family, owners of Purdue Pharma and OxyContin, allegedly have a serious conflict of interest.

Members of the Sackler family–the wealthy owners behind Purdue Pharma and OxyContin—paid upwards of $19 million in donations to The National Academies of Sciences, Engineering and Medicine, a powerful institution that advises U.S. opioid policy, according to a bombshell report by The New York Times.

The Times outlined a series of events that pose a possible conflict of interest. Dr. Raymond Sackler, his wife, Beverly, and the couple’s foundation started donating large sums of money to the Academies in 2008, according to treasurer reports. They died in 2017 and 2019, respectively. Dame Jillian Sackler also made millions of dollars’ worth of donations to the Academies beginning in 2000. The Academies invested the funds, growing to over $31 million by the end of 2021.

The allegations continue: The Pain Care Forum, a group co-founded by Burt Rosen, the Purdue lobbyist at the time, pushed for legislation introduced in 2007 and 2009 that included plans calling for an Academies report to “increase the recognition of pain as a significant public health problem.”

If the allegations are true, they present a serious conflict of interest. So the Times called upon Michael Rehn Von Korff—a medical researcher who studies the treatment of chronic pain, among other fields, for insight on the matter.

“I didn’t know they were taking private money,” Von Korff told The New York Times. “It sounds like insanity to take money from principals of drug companies and then do reports related to opioids. I am really shocked.”

Last Prisoner Project founder Steve DeAngelo posted the report on Instagram and called the revelations “disgusting.” Medical cannabis is frequently used as an alternative to opioids for some situations.

The Role of OxyContin in the Opioid Crisis

OxyContin was developed and patented in 1996 by Purdue Pharma L.P. and was originally available in multiple doses, the U.S. Department of Justice notes. At first, it appeared that OxyContin revolutionized medicine, but then the opioid epidemic unfolded. 

According to the U.S. Department of Health & Human Services, (HHS) over 760,000 people have died since 1999 from a drug overdose, with nearly 75% of drug overdose deaths in 2020 involving an opioid. The Centers for Disease Control and Prevention reports that the number of drug overdose deaths “quintupled since 1999.”

A 2011 The National Academies of Sciences, Engineering and Medicine report claims that 100 million Americans suffered from chronic pain—one-third of the entire U.S. population—and while that’s often cited by government organizations, now that number is being challenged as preposterous. That report influenced the U.S. Food and Drug Administration to approve at least one powerful opioid, Zohydro, which is a slow release hydrocodone.

In 2016, just months after the National Academies scooped up a $10 million Sackler family donation, the F.D.A. asked the institution to form a committee to create new recommendations on opioids. But the Academies were blamed for having sketchy ties to opioid makers, including Purdue Pharma. Four people were removed from the panel after that incident.

The National Academies of Sciences, Engineering and Medicine was created by Abraham Lincoln, and U.S. laws are shaped by the data it releases. For the past few decades though, the academy was utilized to combat the American opioid crisis.

The opioid crisis is complex and it’s difficult to distinguish between people who are addicted and people who genuinely have high levels of pain. But the overdose death toll is impossible to ignore as it surpasses death toll numbers from war and sickness. In 2017, the HHS declared the opioid crisis a public health emergency.

There is also another side to the story. Megan Lowry from the National Academies told The New York Times that the Sackler donations “were never used to support any advisory activities on the use of opioids or on efforts to counter the opioid crisis,” and that they are prevented from returning the Sackler donations because of legal restrictions.

Source: https://hightimes.com/news/owners-of-oxycontin-maker-paid-19m-to-institution-that-advises-opioid-policy/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News